RBC Capital Cuts PT on Legend Biotech Corporation (LEGN) to $62 From $66 – Here’s Why

Core Insights - Legend Biotech Corporation (NASDAQ:LEGN) is identified as a high growth healthcare stock with significant investment potential, despite recent price target adjustments by analysts [1][2] Group 1: Financial Performance and Analyst Ratings - RBC Capital reduced its price target for Legend Biotech to $62 from $66 while maintaining an Outperform rating, citing a disconnect between share price and business fundamentals [1] - Morgan Stanley also updated its price target to $49 from $50, reiterating an Overweight rating, and is awaiting further data from ongoing studies [2] Group 2: Company Overview - Legend Biotech is a clinical-stage company focused on developing, discovering, manufacturing, and commercializing novel therapies for oncology and other indications, utilizing advanced cell therapies across various technology platforms [3]